Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 296-304

  Zhu, Andrew X ^a   Chen, David ^b   He, Wei ^b   Kanai, Masayuki ^b   Voi, Maurizio ^b   Chen, Li Tzong ^c,d,e   Daniele, Bruno ^f   Furuse, Junji ^g   Kang, Yoon Koo ^h   Poon, Ronnie T P ⁱ   Vogel, Arndt ^j   Chiang, Derek Y ^k  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f G RUMMO HOSPITAL   (Italy)

^g KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ UNIVERSITY OF HONG KONG   (Hong Kong)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

more..

Author keywords

c Met; Everolimus; mTOR; Next generation sequencing; PI 3 kinase pathway; Tsc2

Indexed keywords

ALPHA FETOPROTEIN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BIOLOGICAL MARKER; COLLAGEN TYPE 4; EVEROLIMUS; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; PLACENTAL GROWTH FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; SORAFENIB; TUBERIN; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE COURSE; DNA SEQUENCE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POTENTIAL DIFFERENCE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; VIRUS ETIOLOGY; CLINICAL TRIAL; LIVER TUMOR; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84970021960     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.015     Document Type: Article

References (56)

1. [1] El-Serag, H.B., Hepatocellular carcinoma. N Engl J Med 365 (2011), 1118–1127.
2. [2] Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
3. [3] Llovet, J.M., Villanueva, A., Lachenmayer, A., Finn, R.S., Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12 (2015), 408–424.
4. [4] Arao, T., Ueshima, K., Matsumoto, K., Nagai, T., Kimura, H., Hagiwara, S., et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 57 (2013), 1407–1415.
5. [5] Llovet, J.M., Hernandez-Gea, V., Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 20 (2014), 2072–2079.
6. [6] Chaiteerakij, R., Addissie, B.D., Roberts, L.R., Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol 13 (2015), 237–245.
7. [7] Zucman-Rossi, J., Villanueva, A., Nault, J.C., Llovet, J.M., Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149 (2015), 1226–1239.
8. [8] Schoenleber, S.J., Kurtz, D.M., Talwalker, J.A., Roberts, L.R., Gores, G.J., Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100 (2009), 1385–1392.
9. [9] Llovet, J.M., Pena, C.E.A., Lathia, C.D., Shan, M., Meinhardt, G., Bruix, J., et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18 (2012), 2290–2300.
10. [10] Boyault, S., Rickman, D.S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2007), 42–52.
11. [11] Chiang, D.Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008), 6779–6788.
12. [12] Hoshida, Y., Nijman, S.M.B., Kobayashi, M., Chan, J.A., Brunet, J.-P., Chiang, D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69 (2009), 7385–7392.
13. [13] Nault, J.C., Mallet, M., Pilati, C., Calderaro, J., Bioulac-Sage, P., Laurent, C., et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun, 4, 2013.
14. [14] Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T.D., Gong, Z., et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 23 (2013), 1422–1433.
15. [15] Cleary, S.P., Jeck, W.R., Zhao, X., Chen, K., Selitsky, S.R., Savich, G.L., et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58 (2013), 1693–1702.
16. [16] Ahn, S.-M., Jang, S.J., Shim, J.H., Kim, D., Hong, S.-M., Sung, C.O., et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60 (2014), 1972–1982.
17. [17] Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46 (2014), 1267–1273.
18. [18] Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47 (2015), 505–511.
19. [19] Laurent-Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120 (2001), 1763–1773.
20. [20] Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Ben Maad, I., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44 (2012), 694–698.
21. [21] Amaddeo, G., Cao, Q., Ladeiro, Y., Imbeaud, S., Nault, J.-C., Jaoui, D., et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut 64 (2015), 820–829.
22. [22] Zhu, A.X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H.Y., et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial. JAMA 312 (2014), 57–67.
23. [23] Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
24. [24] Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43 (2015), D805–D811.
25. [25] Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J.L., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14 (2013), 55–63.
26. [26] Altman, D.G., McShane, L.M., Sauerbrei, W., Taube, S.E., Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med, 9, 2012, e1001216.
27. [27] Tovar, V., Alsinet, C., Villanueva, A., Hoshida, Y., Chiang, D.Y., Sole, M., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 52 (2010), 550–559.
28. [28] Kaposi-Novak, P., Lee, J.-S., Gomez-Quiroz, L., Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116 (2006), 1582–1595.
29. [29] Kondo, S., Ojima, H., Tsuda, H., Hashimoto, J., Morizane, C., Ikeda, M., et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol 18 (2013), 207–213.
30. [30] Lee, S.J., Lee, J., Sohn, I., Mao, M., Kai, W., Park, C.-K., et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res 33 (2013), 5179–5186.
31. [31] Sahin, F., Kannangai, R., Adegbola, O., Wang, J.Z., Su, G., Torbenson, M., MTOR and P70S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10 (2004), 8421–8425.
32. [32] Huynh, H., Hao, H.-X., Chan, S.L., Chen, D., Ong, R., Soo, K.C., et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus. Mol Cancer Ther 14 (2015), 1224–1235.
33. [33] Magnuson, B., Ekim, B., Fingar, D.C., Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441 (2012), 1–21.
34. [34] Villanueva, A., Chiang, D.Y., Newell, P., Peix, J., Thung, S., Alsinet, C., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008), 1972–1983.
35. [35] Weigelt, B., Warne, P.H., Downward, J., PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30 (2011), 3222–3233.
36. [36] Wagle, N., Grabiner, B.C., Van Allen, E.M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 371 (2014), 1426–1433.
37. [37] Iyer, G., Hanrahan, A.J., Milowsky, M.I., Al-Ahmadie, H., Scott, S.N., Janakiraman, M., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 2012 221–221.
38. [38] Voss, M.H., Hakimi, A.A., Pham, C.G., Brannon, A.R., Chen, Y.-B., Cunha, L.F., et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 20 (2014), 1955–1964.
39. [39] Yoon, D.H., Ryu, M.H., Park, Y.S., Lee, H.J., Lee, C., Ryoo, B.Y., et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106 (2012), 1039–1044.
40. [40] Nishi, T., Iwasaki, K., Ohashi, N., Tanaka, C., Kobayashi, D., Nakayama, G., et al. Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Lett 331 (2013), 220–229.
41. [41] Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.M., Abadie-Lacourtoisie, S., et al. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol 26 (2015), 120–125.
42. [42] Kaibori, M., Shikata, N., Sakaguchi, T., Ishizaki, M., Matsui, K., Iida, H., et al. Influence of rictor and raptor expression of mTOR signaling on long-term outcomes of patients with hepatocellular carcinoma. Dig Dis Sci 60 (2015), 919–928.
43. [43] Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C.A., Barys, L., Maira, S.-M., et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8 (2009), 742–753.
44. [44] Fernandez, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., Bosch, J., Angiogenesis in liver disease. J Hepatol 50 (2009), 604–620.
45. [45] Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 4 (2014), 730–743.
46. [46] Kaseb, A.O., Morris, J.S., Hassan, M.M., Siddiqui, A.M., Lin, E., Xiao, L., et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29 (2011), 3892–3899.
47. [47] Yegin, E.G., Siykhynnbayev, A., Eren, F., Bekiroglu, N., Ozdogan, O.C., Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Ann Hepatol 12 (2013), 915–925.
48. [48] Zhan, P., Qian, Q., Yu, L.-K., Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr 2 (2013), 209–215.
49. [49] Zhu, A.X., Ancukiewicz, M., Supko, J.G., Sahani, D.V., Blaszkowsky, L.S., Meyerhardt, J.A., et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 19 (2013), 1557–1566.
50. [50] Nagaoka, S., Yoshida, T., Akiyoshi, J., Akiba, J., Hisamoto, T., Yoshida, Y., et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 23 (2010), 1647–1654.
51. [51] Guan, D.-X., Shi, J., Zhang, Y., Zhao, J.-S., Long, L.-Y., Chen, T.-W., et al. Sorafenib enriches EpCAM positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology 62 (2015), 1791–1803.
52. [52] Goyal, L., Muzumdar, M.D., Zhu, A.X., Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 19 (2013), 2310–2318.
53. [53] Rimassa, L., Porta, C., Borbath, I., Daniele, B., Finn, R.S., Raoul, J.-L., et al. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. Hepatic Oncol 1 (2014), 181–188.
54. [54] Rimassa, L., Abbadessa, G., Personeni, N., Porta, C., Borbath, I., Daniele, B., et al. Tivantinib in pretreated hepatocellular carcinoma (HCC): tumor and plasma biomarker analysis from the randomized controlled phase 2 trial (RCT). International Liver Cancer Association; 2015. 2015, International Liver Cancer Association, Paris p. O-029.
55. [55] Chen, W., Wu, J., Shi, H., Wang, Z., Zhang, G., Cao, Y., et al. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int, 2014 764981–764981.
56. [56] Firtina Karagonlar, Z., Koc, D., Iscan, E., Erdal, E., Atabey, N., Elevated HGF experssion as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in HCC cells. Cancer Sci, 2016 [epub ahead of print].